Medscape

Spinal Cord Stimulation for Long-term Treatment of Severe Angina Pectoris

The future group of patients with refractory angina pectoris will be different from today's patients and represent a 'moving target' as risk factors, efficacy of treatment and indications continue to ...
Nature

Mild increase in coronary sinus pressure with coronary sinus reducer stent for treatment of refractory angina

We thank Professor Mohl and colleagues for raising the concept of 'embryonic recall' as an alternative link between coronary sinus activation and cardiac regeneration. 1 This well-written viewpoint ...
National Institute for Health and Care Excellence

Percutaneous laser revascularisation for refractory angina pectoris

Angina pectoris is chest discomfort, often described as pressure or pain, typically occurring on exertion. It is caused by inadequate delivery of oxygen to the heart muscle, usually because of ...
Business Wire

XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina

WAYNE, Pa.--(BUSINESS WIRE)--XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced the completion of the Phase 1 ...
Nasdaq

Neovasc Announces FDA Advisory Panel Result on Neovasc Reducer™ Medical Device for the Treatment of Refractory Angina

VANCOUVER and MINNEAPOLIS, Oct. 28, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire-- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the United States Food and Drug ...
Business Wire

XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

WAYNE, Pa.--(BUSINESS WIRE)--XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced completion of the Phase 2 ...
mp.pl

Left ventricular systolic function of patients with refractory angina pectoris treated by percutaneous myocardial laser revascularisation, long-term follow-up results

Krzysztof Żmudka, Jarosław Trębacz, Piotr Podolec, Maria Olszowska, Marta Hlawaty, Magdalena Kostkiewicz, Paweł Rudziński, Jerzy Sadowski, Wiesława Tracz ...
Nasdaq

Neovasc's Tiara(TM) for Treatment of Mitral Regurgitation and Neovasc Reducer(TM) for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference

VANCOUVER, Sept. 30, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
Business Insider

Outlook on the Global Refractory Angina Industry to 2030 - 11-Year Forecast of Refractory Angina Epidemiology

Dublin, Sept. 09, 2020 (GLOBE NEWSWIRE) -- The "Refractory Angina (RA) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...
Time

Medicine: Angina Pectoris

When a robust man suddenly drops dead and the newspapers report “heart failure,” the probability is that he died during an attack of angina pectoris. If he had gone to his doctor the day before, the ...
National Institute for Health and Care Excellence

Transmyocardial laser revascularisation for refractory angina pectoris

Angina pectoris is chest discomfort, often described as pressure or pain, typically occurring on exertion. It is caused by inadequate delivery of oxygen to the heart muscle, usually because of ...